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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
1. Evaluate whether adding PBO to pyrethroid LLINs increases the epidemiological and entomological effectiveness of the nets.
2. Compare the effects of PBO-LLINs currently in commercial development or on the market with their non-PBO equivalent in
relation to:
a. malaria infection (prevalence or incidence);
b. entomological outcomes.
B A C K G R O U N D
Description of the condition
Substantial progress has been made in malaria control in the
21st century. Some studies estimate that the clinical incidence of
Plasmodium falciparum malaria has dropped by 40% since 2000
equating to the prevention of 663 million cases (Bhatt 2015;
WHO-GMP 2015). The main focus of malaria control relies on
the use of long-lasting insecticidal nets (LLINs), indoor residual
spraying (IRS), and treatment with artemisinin-based combina-
tion therapy (ACT). Of these methods, 68% of cases averted have
been attributed to the use of LLINs (Bhatt 2015). This method
of malaria prevention is particularly effective in Africa where the
major malaria vectors, Anopheles gambiae and Anopheles funestus,
are largely endophagic (feed indoors) and endophilic (rest indoors
after blood-feeding).
Currently only one insecticide class, the pyrethroids, is commonly
used to treat LLINs; pyrethroids have the required dual prop-
erties of low mammalian toxicity and rapid insecticidal activity
(Zaim 2000), and their repellent or contact irritant effects may
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enhance the personal protection of LLINs. Unfortunately, resis-
tance to pyrethroids is now widespread in African malaria vectors
(Ranson 2016). This may be the result of mutations in target-site
proteins (target-site resistance) (Ranson 2011; Ridl 2008), which
results in reduced sensitivity or increased activity of detoxification
enzymes (metabolic resistance) (Mitchell 2012; Stevenson 2011),
or other as yet poorly-described resistance mechanisms, or both.
The evolution of insecticide resistance and its continuing spread
threatens the operational success of malaria vector control inter-
ventions. The current impact of this resistance on malaria trans-
mission is largely unquantified andwill vary depending on the level
of resistance, malaria endemicity, and proportion of the human
population using LLINs (Churcher 2016). However, it is gener-
ally accepted that resistance will eventually erode the efficacy of
pyrethroid-only LLINs and that innovation in the LLIN market
is essential to maintain the efficacy of this preventative measure
(MPAC 2016).
Description of the intervention
One way of controlling insecticide-resistant mosquito popula-
tions is through the use of insecticide synergists. Synergists are
generally non-toxic and act by enhancing the potency of insecti-
cides. Piperonyl butoxide (PBO) is a synergist that inhibits spe-
cific metabolic enzymes withinmosquitoes, and has been incorpo-
rated into pyrethroid-treated LLINs to form PBO-combination
nets (thereafter referred to as PBO-LLINs). Insecticide-synergist
combination nets represent a new product class with the capacity
to impact against insecticide resistant populations. However, there
is no consensus of their effectiveness in reducing malaria cases in
comparison to “standard” LLINs (WHO-GMP 2015).
Currently there are five PBO-LLINs that are either in development
or on the market: Olyset® Plus, PermaNet® 3.0, Veeralin® LN,
and DawaPlus 3.0 and 4.0. Olyset Plus, which is manufactured by
Sumitomo Chemical Company Ltd, is a polyethylene net treated
with permethrin (20 g/kg ± 25%) and PBO (10 g/kg ± 25%)
across the whole net (Sumitomo 2013). PermaNet 3.0, which is
manufactured byVestergaard Frandsen, is amixed polyester (sides)
polyethylene (roof ) net treated with deltamethrin and PBO; PBO
is only found on the roof of the net (25 g/kg ± 25%) and the
concentration of deltamethrin varies depending on location (roof:
4.0 g/kg ± 25%) and yarn type (sides: 75 denier with 70 cm lower
border 2.8 g/kg±25%, 100denierwithout border 2.1 g/kg± 25%)
(Vestergaard 2015). Veeralin LN,manufactured byVectorControl
Innovations Private Ltd, is a polyethylene net treated with alpha-
cypermethrin (6.0 g/kg) and PBO (2.2 g/kg) across the whole
net (WHOPES 2016). DawaPlus 3.0 and 4.0 are manufactured
by Tana Netting, UAE and contain PBO on the roof only (3.0)
or on all sides (4.0); Deltamethrin suspension concentrate (SC)
is coated on knitted multifilament polyester fibres, at the target
dose of 1.33 g/kg in 75-denier yarn and 1 g/kg in 100- denier
yarn, corresponding to 40 mg of deltamethrin per LN m², using
a polymer as a binder.
How the intervention might work
PBO inhibits metabolic enzyme families, in particular the cy-
tochrome P450 enzymes that detoxify or sequester pyrethroids.
Increased production of P450s is thought to be the most po-
tent mechanism of pyrethroid resistance in malaria vectors, and
pre-exposure to PBO has been shown to restore susceptibility to
pyrethroids in laboratory bioassays on multiple pyrethroid-resis-
tant vector populations (Churcher 2016).
Widespreaduse of conventional LLINsprovides both personal and
community protection frommalaria (Bhatt 2015; Lengeler 2004).
However, in areas where the mosquito populations are resistant
to pyrethroids, experimental hut trials (as described in the ‘Types
of studies’ section) have shown that mosquito mortality rates and
protection from blood-feeding are substantially reduced (Abílio
2015; Awolola 2014; Bobanga 2013; N’Guessan 2007; Riveron
2015; Yewhalaw 2012). The addition of PBO to pyrethroids in
LLINs can restore the killing effects of LLINs in areas where this
has been eroded by insecticide resistance. LLINs that contain PBO
have been evaluated in multiple experimental hut trials across
Africa (Adeogun 2012; Corbel 2010; Koudou 2011; N’Guessan
2010; Pennetier 2013; Tungu 2010). In most settings, the PBO-
LLINs resulted in higher rates of mosquito mortality and greater
blood-feeding inhibition than conventional LLINs, although the
magnitude of this effect was variable.
Why it is important to do this review
All LLINs approved by the World Health Organization Pesticide
Evaluation Scheme (WHOPES) contain pyrethroids as the sole
active ingredient. Five LLINs that contain PBO have interim ap-
proval but these are not in widespread use (WHOPES 2016). As
PBO-LLINs are more expensive than conventional LLINs, it is
important to determine if they are superior to conventional LLINs
and, if so, under what circumstances, to enable cost effectiveness
studies to be performed to inform procurement decisions.
An Expert Review Group (ERG) commissioned by the World
Health Organization (WHO) previously recommended condi-
tions for the use of pyrethroid LLINs treated with PBO (WHO-
GMP 2015), and advised that although “PBO LLINs appear to
have an increased efficacy in certain settings…the evidence is still
limited to justify a complete switch from pyrethroid-only LLINs
to PBO LLINs across all settings”. A meta-analysis of PBO-LLIN
performance in experimental hut studies was used to parameterize
a malaria transmission model to predict the public health bene-
fit of PBO-LLINs (Churcher 2016). Although it provided a tool
to predict the malaria transmission setting in which PBO-LLINs
would have greatest impact, the reliance on models was not widely
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accepted by the ERG, which emphasized the need for pilot ex-
ploratory implementation with robust evaluation. More recently,
the Vector Control Advisory Group has issued guidance on the
evidence requirements for new vector control tools and recom-
mended at least two trials with epidemiological endpoints for ’first
in class’ products (WHO 2017).
In an attempt to assess the evidence of the effectiveness of PBO-
LLINs against African malaria vectors in areas of insecticide re-
sistance, we will conduct a systematic review of all relevant stud-
ies and we will examine both epidemiological and entomological
endpoints. We appreciate that the evaluation of PBO will depend
on studies where the background insecticide and dose is the same
in both intervention and control groups. We are aware that some
studies will have evaluated PBO-LLINs against pyrethroid-only
LLINs with different background insecticides and doses, which
confound the effects. We will include and describe these studies
in this Cochrane Review, and appraise the findings in the light of
the comparisons and potential confounding using GRADE.
One of the problems with the field is that PBO-LLINs are com-
mercial products. The PBO-LLINs currently undergoing clini-
cal trials have had additional alterations made to them, such as
changing the concentration or rate at which the pyrethroid is re-
leased. However, these are the products for which policy decisions
are needed, based on evidence related to their relative effective-
ness. There are no clinical trials underway comparing nets that are
identical except for the addition of PBO. Thus in this Cochrane
Review we seek direct evidence for PBO alone impacting on the
effectiveness of nets, and also will examine the evidence concern-
ing the effectiveness of commercial products. These comparisons
will carefully detail other potential confounding factors to be sure
that generic recommendations that might be made take this into
account.
O B J E C T I V E S
1. Evaluate whether adding PBO to pyrethroid LLINs increases
the epidemiological and entomological effectiveness of the nets.
2. Compare the effects of PBO-LLINs currently in commercial
development or on the market with their non-PBO equivalent in
relation to:
a. malaria infection (prevalence or incidence);
b. entomological outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
For objective 1 we will include a) laboratory bioassay (for example,
cone bioassays, tunnel tests) studies; b) experimental hut trials,
and c) village trials (WHOPES Phase I, II and III studies).
For objective 2 (a and b) we will include experimental hut studies
and village trials (WHOPESPhase II studies andPhase III studies).
See Table 1 for WHOPES definitions in detail.
Types of participants
Mosquitoes
Anopheles gambiae complex or Anopheles funestus group. Included
studies must test a minimum of 50 mosquitoes per study arm.
We will include all mosquito populations and we will examine the
insecticide resistance level (measured using phenotypic resistance)
during data analysis.
Humans
Adults and children living in malaria-endemic areas where




Combination LLIN treated with both PBO and a pyrethroid in-
secticide. LLINsmust have received aminimum of interim-WHO
approval (Table 2), and LLINs must be treated with a WHO-rec-
ommended dose of pyrethroid (Table 3).
Control
Conventional LLINs that contain pyrethroid only.
For objective 1 nets of the same fabric must be treated with the
same insecticide, dose and release rate as the intervention net to
allow direct evaluation of the addition on PBO.
For objective 2 (a and b), nets can be treated with the same insec-
ticide at different doses than the intervention net to allow critical
appraisal of all PBO-LLINs currently in development or on the
market, and not singular products.
Types of outcome measures
Studiesmust include at least one of the followingoutcomes to be el-
igible for inclusion: mosquito mortality, blood-feeding, sporozoite
rate, parasite presence, clinical malaria confirmation, not passed
through net, deterrence, exophily,mosquito density, or parity rate.
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Primary outcomes
Epidemiological
• Parasite presence: presence of malaria parasites through
microscopy of blood or Rapid Diagnostic Tests (RDTs).
• Clinical malaria confirmation: clinical diagnosis based on
the participant’s symptoms and on physical findings at
examination.
Entomological
• Mosquito mortality: immediate death or delayed death (up
to 24 hours), or both, measured as a proportion of total
mosquito number. A mosquito is classified as dead if it is
immobile, cannot stand or fly, or shows no sign of life.
• Mosquito knock-down: mosquito ‘mortality’ recorded one
hour post-insecticide exposure, termed ‘knock-down’ as some
mosquitoes may recover during the 24-hour recovery period
before mosquito mortality is recorded at 24 hours post-exposure.
• Blood-feeding success: number of mosquitoes that have
blood-fed (alive or dead).




• Not passed through net: the number of mosquitoes that do
not pass through a holed PBO-LLIN to reach a human bait
relative to a standard LLIN.
• Deterrence: the number of mosquitoes that enter a hut that
is using a PBO-LLIN relative to the number of mosquitoes
found in a control hut that is using a standard LLIN.
• Exophily: the proportion of mosquitoes found in exit/
veranda traps of a hut that is using a PBO-LLIN, relative to the
control hut that is using a standard LLIN.
• Mosquito density: measured using all standard methods,
such as window exit traps, indoor resting collections, floor sheet
collections, pyrethrum spray catch, and light traps.
• Parity rate: percentage of parous mosquitoes which are
detected by mosquito ovary dissections.
Search methods for identification of studies
Wewill attempt to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress). We have presented the MEDLINE search strategy in
Appendix 1.
Electronic searches
Vittoria Lutje, the CIDG Information Specialist, will search
the following databases using the search terms and strategy de-
scribed in Appendix 1: the Cochrane Infectious Diseases Group
(CIDG) Specialized Register; the Central Register of Controlled
Trials (CENTRAL), published in the Cochrane Library; MED-
LINE (Pubmed); Embase (OVID); Web of Science Citation
Index Expanded; and BIOSIS Previews. We will also search
the WHO International Clinical Trials Registry Platform (IC-
TRP; www.who.int/ictrp/en/) and ClinicalTrials.gov (https://
clinicaltrials.gov/ct2/home) for trials in progress, and will use
“piperonyl butoxide”, bednet*, ITN, and LLIN as search terms.
Searching other resources
We will contact the following organizations for unpublished data:
the President’s Malaria Initiative (PMI); the Innovative Vector
Control Consortium (IVCC); Vestergaard Frandsen; Sumitomo
Chemical Company Ltd; Vector Control Innovations Private
Ltd; Endura SpA; and the WHO Pesticide Evaluation Scheme
(WHOPES). We will check the reference lists of studies identified
by the above methods.
Data collection and analysis
For the primary analysis we will stratify data by study type only.
During subgroup analysis we will analyse the data by both study
design and mosquito insecticide resistance level (Table 4; Table 5),
or study design and product type if applicable.
Selection of studies
Two review authors (KG and NL) will independently screen titles
and abstracts of all retrieved references based on the inclusion cri-
teria (Table 6). We will resolve any inconsistencies between the re-
view authors’ selections by discussion. If we are unable to reach an
agreement, we will consult the third review author (HR). We will
retrieve the full-text study reports for all potentially relevant cita-
tions. Two review authors will independently screen the full-text
articles and identify studies for inclusion, and identify and record
reasons for exclusion of ineligible studies in a ‘Characteristics of
excluded studies’ table.We will resolve any disagreements through
discussion or, if required, we will consult the third review author
(HR).Wewill identify and exclude duplicates and collate multiple
reports of the same study so that each study, rather than each re-
port, is the unit of interest in the review. We will record the selec-
tion process in sufficient detail to complete a Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) flow
diagram (Moher 2009).
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Data extraction and management
After selection, we will summarize all included studies according
to the tables in Appendix 2. Two review authors (KG and NL)
will independently extract data from the included studies using
the pre-designed data extraction form (Appendix 3). If data are
missing from an included study, we will contact the study authors
for further information. We will enter data into Review Manager
(RevMan) (RevMan 2014).
Assessment of risk of bias in included studies
Two review authors (KGandNL)will independently assess the risk
of bias of each included study using a set of predetermined criteria
specific to each study type adapted from Strode 2014 (Appendix
4). We will assign a classification of either low, high, or unclear
risk of bias for each component. For all included studies we will
assess whether any study authors had submitted any conflicts of
interest that may have biased the study methodology or results.
Laboratory bioassays
For laboratory bioassays we will assess four criteria: comparability
of mosquitoes between LLIN/PBO-LLIN arms (for example, all
female, same age, and non-blood-fed), observers blinded, incom-
plete outcome data, and raw data reported for both net treatments.
Experimental hut trials
For experimental hut trials we will assess 10 criteria: comparabil-
ity of mosquitoes between LLIN/PBO-LLIN arms (for example,
species composition), collectors blinded, sleepers blinded, alloca-
tion of treatments, rotation of treatments, sleeper bias accounted
for, standardized hut design, cleaning of huts between treatments,
incomplete outcome data, and raw data reported.
Village trials
We will assess six criteria for village trials: comparability of
mosquitoes between LLIN/PBO-LLIN households (for example,
species composition), collectors blinded, household blinded, al-
location of treatments, incomplete outcome data, and raw data
reported.
Measures of treatment effect
For dichotomous data we will present the risk ratio (RR), for
continuous data wewill present themean difference, and for count
data we will present the rate ratios. We will present all results with
95% confidence intervals (CIs).
Unit of analysis issues
For human studies randomized by hut or village, or both (for ex-
ample, cluster-randomized trials). We will use the adjusted mea-
sure of effect reported in the paper if available. If not, we will ad-
just the effect estimate using an intracluster correlation coefficient
(ICC), and average cluster size (Higgins 2011, Section 16.3.4). If
the included study does not report the ICC value, we will either
use an ICCvalue reported by a similar study or wewill estimate the
ICC value. We will investigate the impact of estimating the ICC
or using an ICC value from another study in sensitivity analyses.
Dealing with missing data
In the case of missing data, we will contact the study authors to
retrieve this information. Should this information be unavailable,
where applicable to the study design, we will conduct a complete
case-analysis, and we will investigate the impact of missing data
via imputation using a best-worst case scenario analysis.
Where information on mosquito insecticide resistance was not
collected at the time of the study, the study authors will determine
a suitable proxy. The proxy resistance data must be from the same
area, conducted within three years of the study, and using the same
insecticide, dose, and mosquito species. More than 50 mosquitoes
per insecticide should have been tested using an appropriate con-
trol. Where no resistance data is available, we will class the resis-
tance status as unclassified. If the proxy-resistance places the study
in a borderline (within 1%) position for the subgroup analysis by
resistance level, we will consider it in both the level it is in and the
level it borderlines with.
Assessment of heterogeneity
We will present the results of the included studies in forest plots,
which we will inspect visually to assess heterogeneity (that is, non-
overlapping CIs generally signify statistical heterogeneity).Wewill
also use the Chi² test with a P value of less than 0.1 to indicate
statistical heterogeneity. We will quantify heterogeneity using the
I² statistic andwewill interpret a value greater than75%to indicate
considerable heterogeneity.
Assessment of reporting biases
To analyse the possibility of publication bias, we will use funnel
plots provided there are at least 10 included studies.
Data synthesis
Where appropriate, we will pool the results of the included studies
using meta-analysis. We will analyse the effect of adding PBO to
pyrethroid LLINs, and then compare the effects of PBO-LLINs
currently in development with their non-PBO equivalent.We will
stratify results by type of study and we will examine mosquito re-
sistance status or net type (i.e. product, e.g. Olyset Plus) through
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subgroup analyses. For human outcomeswewill assess whether use
of PBO-LLINs resulted in reduced malaria infection (for exam-
ple, prevalence, incidence) compared to conventional pyrethroid-
only LLINs. One review author (MR) will analyse the data us-
ing Review Manager 5 (RevMan 5) (RevMan 2014), and we will
use the random-effects model (if we detect heterogeneity; the I²
statistic value is more than 50%) or the fixed-effect model (for no
heterogeneity; the I² statistic value is less than 50%). We will not
pool studies in a meta-analysis if it is not clinically meaningful to
do so due to clinical or methodological heterogeneity. If the study
authors stated the adjusted estimates for cluster-RCTs or if we can
calculate these, we will combine these with RCTs; otherwise we
will exclude them.
We will assess the certainty of the evidence using the Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) approach. We will construct ‘Summary of findings’
tables using theGRADEproGuidelineDevelopmentTool (GDT)
software (GRADEpro GDT 2014).
Subgroup analysis and investigation of heterogeneity
We will stratify the results by study type.
We will determine whether mosquito populations are susceptible
or resistant to pyrethroid insecticides based on WHO definitions
(WHOPES 2013; Table 4). Where available, we will use 24-hour
mosquito mortality. However, if this is unavailable, we will use
knock-down 60 minutes after the end of the assay. We will con-
duct a subgroup analysis to examine susceptible versus resistant
mosquitoes using WHO definitions (Table 4). If we observe that
heterogeneity is present, we will perform a second subgroup anal-
ysis to examine the stratification of resistance; we will stratify resis-
tant populations into low, moderate, or high prevalence resistance
(Table 5).
Sensitivity analysis
If applicable, we will perform sensitivity analyses to determine the
effect of exclusion of trials that we consider to be at high risk of
bias. Also, we will perform a sensitivity analysis for missing data
during imputation with best-worst case scenarios.
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A D D I T I O N A L T A B L E S
Table 1. WHOPES classification
WHOPES Phase Definition
WHOPES Phase I. Laboratory bioassays Cone bioassays: these are studies that are conducted in the laboratory setting and
use standard WHO protocols (WHOPES 2013, Section 2.2.1), where mosquitoes
are exposed to a suitable LLIN (treated intervention or untreated control) for three
minutes using a standard plastic WHO cone. Following net exposure, mosquitoes
are transferred to a holding container and maintained on a sugar solution diet while
entomological outcomes (mosquitoes knocked down one hour post-exposure, and
mosquito mortality 24 hours post-exposure) are measured
Tunnel tests: these are studies conducted in the laboratory setting that use standard
WHOprotocols (WHOPES 2013, Section 2.2.2). Mosquitoes are released into a glass
tunnel covered at each end with untreated netting. The intervention or control LLIN
net sample is placed one-third down the length of the tunnel and the net contains nine
holes that enable mosquitoes to pass through. A suitable bait is immobilized in the
shorter section of the tunnel where it is available for mosquito biting. Mosquitoes are
released into the opposite end of the tunnel and must make contact with the net and
locate holes before being able to feed on the bait. After 12 to 15 hours, mosquitoes are
removed from both sections of the tunnel and entomological outcomes (the number
of mosquitoes in each section, mortality, and blood-feeding inhibition at the end of
the assay and 24 hours post-exposure) are recorded
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Table 1. WHOPES classification (Continued)
Wire-ball bioassays: these are studies conducted in the laboratory setting where
mosquitoes are introduced into a wire-ball frame that has been covered with either the
intervention or control LLIN. Mosquitoes are exposed for three minutes, after which
they are transferred to a holding container and entomological outcomes (mosquitoes
knocked down one hour post-exposure, and mosquito mortality 24 hours post-expo-
sure) are measured
WHOPES Phase II. Experimental hut trials WHOPES Phase II experimental hut trials are field trial studies conducted in Africa
where wild mosquito populations or local colonized populations are evaluated. Vol-
unteers or livestock sleep in experimental huts under a purposefully holed LLIN, with
one person or animal per hut. Huts are designed to resemble local housing based on
a West or East African design (WHOPES 2013; Section 3.3.1-2). However they have
identical design features, such as eave gaps or entry slits to allow mosquitoes to enter,
and exit traps to capture exiting mosquitoes. LLINs and volunteers are randomly al-
located to huts and rotated in a Latin square to avoid bias, with huts cleaned between
rotations to avoid contamination. Several nets, including an untreated control net,
can be tested at the same time. Dead and alive mosquitoes are collected each morning
from inside the net, inside the hut, and inside the exit traps. They are then scored as
either blood-fed or non-blood-fed, and either alive or dead, and live mosquitoes are
maintained for a further 24 hours to assess delayed mosquito mortality
WHOPES Phase III. Village trials WHOPES Phase III village trials are village trials conducted in Africa where wild
mosquito populations are evaluated. Villages chosen to be included in the study are
similar in terms of size, housing structure, location, and the data available on the
insecticide resistance status of the local malaria vectors. Households are assigned either
conventional LLINs or PBO-LLINs. Randomization can be at the household or village
level. Adult mosquitoes are collected from the study houses and mosquito density is
measured. An indication of malaria transmission is measured in the study sites either
by recording infections in mosquitoes, malaria prevalence, or malaria incidence
Table 2. WHO-recommended LLINs
Product name Product type Status of WHO recommendation
DawaPlus 2.0 Deltamethrin coated on polyester Interim
DawaPlus 3.0 Combination of deltamethrin coated onto polyester (side
panels), and deltamethrin and PBO incorporated into
polyester (roof )
Interim
DawaPlus 4.0 Deltamethrin and PBO incorporated into polyester Interim
Duranet Alpha-cypermethrin incorporated into polyethylene Full
Interceptor Alpha-cypermethrin coated on polyester Full
LifeNet Deltamethrin incorporated into polypropylene Interim
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Table 2. WHO-recommended LLINs (Continued)
MAGNet Alpha-cypermethrin incorporated into polyethylene Full
MiraNet Alpha-cypermethrin incorporated into polyethylene Interim
Olyset Net Permethrin incorporated into polyethylene Full
Olyset Plus Permethrin and PBO incorporated into polyethylene Interim
Panda Net 2.0 Deltamethrin incorporated into polyethylene Interim
PermaNet 2.0 Deltamethrin coated on polyester Full
PermaNet 3.0 Combination of deltamethrin coated on polyester with
strengthened border (side panels), and deltamethrin and
PBO incorporated into polyethylene (roof )
Interim
Royal Sentry Alpha-cypermethrin incorporated into polyethylene Full
SafeNet Alpha-cypermethrin coated on polyester Full
Veeralin Alpha-cypermethrin and PBO incorporated into
polyethylene
Interim
Yahe Deltamethrin coated on polyester Interim
Yorkool Deltamethrin coated on polyester Full
Abbreviations: LLIN: long-lasting insecticidal net; WHO: World Health Organization.
Table 3. WHO-recommended insecticide products for treatment of mosquito nets for malaria vector control
Insecticide Formulation1 Dosage2
Alpha-cypermethrin SC 10% 20 to 40
Cyfluthrin EW 5% 50
Deltamethrin SC 1%
WT 25%
WT 25% + binder3
15 to 25
Etofenprox EW 10% 200
Lambda-cyhalothrin CS 2.5% 10 to 15
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Table 3. WHO-recommended insecticide products for treatment of mosquito nets for malaria vector control (Continued)
Permethrin EC 10% 200 to 500




Table 4. Definition of resistance level
Outcome Confirmed resistance Suspected resistance Susceptible Unclassified
WHOmosquitomortal-
ity
< 90% 90% to 97 % 98% to 100% Unknown
CDC knock-down < 90% 80% to 97% 98% to 100% Unknown
Abbreviations: CDC: Centers for Disease Control and Prevention; WHO: World Health Organization.
Definition of resistance level based on mosquito mortality (%) after exposure to insecticide in a WHO diagnostic dose assay (WHO
mosquito mortality), or a CDC bottle bioassay (CDC knock-down) using the methodology, diagnostic doses, and diagnostic times
recommended by each test respectively.
Table 5. Stratification of resistance level
Outcome Low Moderate High Unclassified
Mosquito mortality1 61% to 90% 31% to 60% < 30% Unknown
124-hour post-exposure mortality (%).








- State mosquito species
Were a minimum of
50 mosquitoes tested per
study arm?
-
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Table 6. Study inclusion screening form (Continued)
Intervention
Did the study include
an long-lasting insectici-
dal net (LLIN) or insec-
ticide treated net (ITN)?
- State net LLIN or ITN
Was the intervention net











dose of pyrethroid +
PBO.
- State net type
Was the control net ei-
ther of the following?
• A pyrethroid LLIN
of the same fabric
impregnated with the
same insecticide and
dose as intervention net
(objective 1).
• A pyrethroid LLIN
impregnated with the
same insecticide at any
dose (objective 2 (a and
b)).
- State which objective study meets
Study design








- State study type
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Table 6. Study inclusion screening form (Continued)
For laboratory bioassay.




study and village trial.




Did the study include at













Is the study eligible for
inclusion?
- - State reason(s) for exclusion
Discuss with authors
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1) “Piperonyl Butoxide”[Mesh]
2) piperonyl butoxide or PBO [Title/Abstract]
3) 1 or 2
4) Net* OR bednet* OR hammock* OR curtain* OR ITN* OR LLIN* or “Insecticide-Treated Bednet*” or “Insecticide-Treated net*”
[Title/Abstract]
5) Olyset* or PermaNet* or Veeralin [Title/Abstract]
6) “Insecticide-Treated Bednets” [Mesh]
7) 4 or 5 or 6
8) 3 and 7
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This is the preliminary search strategy for MEDLINE (PubMed). It will be adapted for other electronic databases. We will report all
search strategies in full in the final version of the Cochrane Review.
Appendix 2. Study characteristics tables


































































KD M BF NPTN
Abbreviations: KD: knock-down; M: mortality; BF; blood-feeding; NPTN: not passed though net.































M BF D E
Abbreviations: M: mortality; BF; blood-feeding; D: deterrence; E: exophily.
Table 2.5 Study characteristics of the included village trials
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M BF SR MD PR PP CMC
Abbreviations: M: mortality; BF: blood-feeding; SR: sporozoite rate; MD: mosquito density; PR: parity rate; PP: parasite presence;
CMC: clinical malaria confirmation.
Appendix 3. Data extraction tables























BF BF (%) NPTN NPTN
(%)
Abbreviations: BF: blood-feeding; NPTN: not passed through net.























































Abbreviations: BF: blood-feeding; BFI: blood-feeding inhibition; N: number of people.
Table 3.3 Data extracted from village trials
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Abbreviations: BF: blood-feeding; PP: parasite prevalence; CMC: clinical malaria confirmation; N: number of people.
Appendix 4. ‘Risk of bias’ tables
Table 4.1 ‘Risk of bias’ assessment for laboratory bioassays
Study ID Study name Comparability of
mosquitoes in












Abbreviations: LLIN: long-lasting insecticidal nets; PBO: piperonyl butoxide.




























































Table 4.3 ‘Risk of bias’ assessment for village trials
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Abbreviations: LLIN: long-lasting insecticidal nets; PBO: piperonyl butoxide.
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